316 related articles for article (PubMed ID: 32593547)
21. Pegvaliase dosing in adults with PKU: Requisite dose for efficacy decreases over time.
Hollander S; Viau K; Sacharow S
Mol Genet Metab; 2022; 137(1-2):104-106. PubMed ID: 35964530
[TBL] [Abstract][Full Text] [Related]
22. Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase).
Goldfinger M; Zeile WL; Corado CR; O'Neill CA; Tsuruda LS; Laipis PJ; Cooper JD
Mol Genet Metab; 2017 Sep; 122(1-2):33-35. PubMed ID: 28506393
[TBL] [Abstract][Full Text] [Related]
23. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria.
Longo N; Dimmock D; Levy H; Viau K; Bausell H; Bilder DA; Burton B; Gross C; Northrup H; Rohr F; Sacharow S; Sanchez-Valle A; Stuy M; Thomas J; Vockley J; Zori R; Harding CO
Genet Med; 2019 Aug; 21(8):1851-1867. PubMed ID: 30546086
[TBL] [Abstract][Full Text] [Related]
24. Nutrition status of adults with phenylketonuria treated with pegvaliase.
Viau K; Wessel A; Martell L; Sacharow S; Rohr F
Mol Genet Metab; 2021 Aug; 133(4):345-351. PubMed ID: 34116943
[TBL] [Abstract][Full Text] [Related]
25. Pegvaliase: First Global Approval.
Markham A
BioDrugs; 2018 Aug; 32(4):391-395. PubMed ID: 30022433
[TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria.
Hydery T; Coppenrath VA
Drug Target Insights; 2019; 13():1177392819857089. PubMed ID: 31258325
[TBL] [Abstract][Full Text] [Related]
27. First successful outcomes of pegvaliase (PALYNZIQ) in children.
Alfadhel M; Albarakati R
BMC Med Genomics; 2024 Mar; 17(1):76. PubMed ID: 38515136
[TBL] [Abstract][Full Text] [Related]
28. Alternative therapies to address the unmet medical needs of patients with phenylketonuria.
Blau N; Longo N
Expert Opin Pharmacother; 2015 Apr; 16(6):791-800. PubMed ID: 25660215
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.
Lee P; Treacy EP; Crombez E; Wasserstein M; Waber L; Wolff J; Wendel U; Dorenbaum A; Bebchuk J; Christ-Schmidt H; Seashore M; Giovannini M; Burton BK; Morris AA;
Am J Med Genet A; 2008 Nov; 146A(22):2851-9. PubMed ID: 18932221
[TBL] [Abstract][Full Text] [Related]
30. Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
Adams D; Andersson HC; Bausell H; Crivelly K; Eggerding C; Lah M; Lilienstein J; Lindstrom K; McNutt M; Ray JW; Saavedra H; Sacharow S; Starin D; Tiffany-Amaro J; Thomas J; Vucko E; Wessenberg LB; Whitehall K
Mol Genet Metab Rep; 2021 Sep; 28():100790. PubMed ID: 34430209
[TBL] [Abstract][Full Text] [Related]
31. Two years of pegvaliase in Germany: Experiences and best practice recommendations.
Krämer J; Baerwald C; Heimbold C; Kamrath C; Parhofer KG; Reichert A; Rutsch F; Stolz S; Weinhold N; Muntau AC
Mol Genet Metab; 2023 May; 139(1):107564. PubMed ID: 37086569
[TBL] [Abstract][Full Text] [Related]
32. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
Levy HL; Sarkissian CN; Scriver CR
Mol Genet Metab; 2018 Aug; 124(4):223-229. PubMed ID: 29941359
[TBL] [Abstract][Full Text] [Related]
33. Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice.
Winn SR; Dudley S; Scherer T; Rimann N; Thöny B; Boutros S; Krenik D; Raber J; Harding CO
Mol Genet Metab; 2022 May; 136(1):46-64. PubMed ID: 35339387
[TBL] [Abstract][Full Text] [Related]
34. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria.
Bilder DA; Arnold GL; Dimmock D; Grant ML; Janzen D; Longo N; Nguyen-Driver M; Jurecki E; Merilainen M; Amato G; Waisbren S
Am J Med Genet A; 2022 Mar; 188(3):768-778. PubMed ID: 34826353
[TBL] [Abstract][Full Text] [Related]
35. A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.
SriBhashyam S; Marsh K; Quartel A; Weng HH; Gershman A; Longo N; Thomas J; Zori R
Mol Genet Metab Rep; 2019 Dec; 21():100507. PubMed ID: 31497506
[TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.
Sarkissian CN; Gámez A; Wang L; Charbonneau M; Fitzpatrick P; Lemontt JF; Zhao B; Vellard M; Bell SM; Henschell C; Lambert A; Tsuruda L; Stevens RC; Scriver CR
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20894-9. PubMed ID: 19095795
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.
Sarkissian CN; Kang TS; Gámez A; Scriver CR; Stevens RC
Mol Genet Metab; 2011 Nov; 104(3):249-54. PubMed ID: 21803624
[TBL] [Abstract][Full Text] [Related]
38. Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity.
Larimore K; Nguyen T; Badillo B; Lau K; Zori R; Shepherd G; Zoog SJ; Weng HH; Gupta S
J Immunol Methods; 2019 May; 468():20-28. PubMed ID: 30880261
[TBL] [Abstract][Full Text] [Related]
39. Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase.
Rocha JC; Bausell H; Bélanger-Quintana A; Bernstein L; Gökmen-Özel H; Jung A; MacDonald A; Rohr F; van Dam E; Heddrich-Ellerbrok M
Mol Genet Metab Rep; 2021 Sep; 28():100771. PubMed ID: 34094869
[TBL] [Abstract][Full Text] [Related]
40. Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies.
McWhorter N; Dhillon J; Hoffman J
J Acad Nutr Diet; 2022 Jul; 122(7):1283-1295.e3. PubMed ID: 34968752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
